Newron Pharmaceuticals S p A : announces AGM 2024 results

Ad hoc announcement pursuant to Art. 53 LR

Newron announces AGM 2024 results

Milan, Italy, April 17, 2024, 11:30 am CET - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda for the ordinary part of the AGM 2024 held today. The motions on the agenda for the extraordinary part of the meeting were not put to vote, due to the required quorum not being reached.

Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: "We thank all our shareholders for their ongoing trust and longstanding support. Newron's total available cash resources together with the initial proceeds deriving from the subscription agreement signed post-periodwill fund the Company's planned development programs and operations well into 2025 and thus well beyond the current key value inflection points in our pipeline. Last but not least we welcome Margarita Chavez as newly elected, independent Board member; we are looking forward to working with her and are convinced that her more than 20 years of dealmaking expertise and leadership in the pharmaceutical industry will be considerably beneficial for Newron."

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information, please contact:

Newron

Stefan Weber - CEO, [phone], [e-mail]

UK/Europe

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting, [phone], [e-mail]

Switzerland

Valentin Handschin, IRF , [phone], [e-mail]

Germany/Europe

Anne Hennecke / Caroline Bergmann, MC Services, [phone], [e-mail]

USA

Paul Sagan, LaVoieHealthScience, [phone], Ext. 112, [e-mail]

1/1